Interpace Diagnostics Presents Data from Multicenter Registry Study of Thyroid Cancer
Clinical Lab Products
At the recent annual meeting of the
“This data represents an important milestone for our company,” says
For the past two years, data from more than 300 patients has been accumulated in support of the study. A main objective of the study is to establish the utility of the company’s ThyGenX mutational panel, in combination with its ThyraMIR microRNA classifier, for correctly identifying those patients for whom surgery is not necessary. Recently, Interpace launched an expanded mutation panel called ThyGeNEXT, which includes additional markers such as ALK, PTEN, RET, and TERT, among others.
According to the
Like ThyGenX, ThyGeNEXT utilizes next-generation sequencing (NGS) to identify more than 150 genetic alterations associated with all forms of thyroid cancer, including follicular, medullary, and papillary thyroid carcinomas. According to the
Molecular testing using ThyGenX has historically been shown to reduce the rate of unnecessary surgeries in indeterminate cases. To date, Interpace has performed ThyGenX and ThyraMIR testing on more than 25,000 patients. The company expects to continue collecting cases for the thyroid registry, which will provide the basis of a peer-reviewed publication examining the effects of ThyGenX and ThyraMIR testing on physicians’ treatment decisions in real-world settings. The company is also adding data to the thyroid registry in order to report on the utility of the expanded mutation panel, ThyGeNEXT, over time.
For more information, visit
- Sistrunk J, Shifrin A, Frager M, et al. Outcomes of patients with thyroid nodules clinically tested using a combination of mutation and microRNA classification: interim results of a multicenter registry study [short call poster 42]. Thyroid. 2018;28(S1):A-184; doi: 10.1089/thy.2018.29071.sc.abstracts.